EHDN statement on the pausing of dosing in the endorsed clinical trials VIBRANT and AMT-130
/pausing-endorsed-clinical-trials/… […]
/pausing-endorsed-clinical-trials/… […]
The 3rd Congress of the European Academy of Neurology (EAN) took place in Amsterdam, June 24-27, with a large attendance of more than 6000 delegates. This was the… […]
…The EHDN newsletter (archive) aims to communicate the network’s activities and other developments of interest in the field of Huntington’s disease to the lay community, healthcare professionals and scientists…. […]
…Lesley was a well-known figure in the HD community and had collaborators across the globe. She has been embedded in HD research for most of her career and was central… […]
…Currently, I am involved in clinical and scientific research both nationally and internationally regarding HD. I believe I could make a contribution to the tasks of the Executive Committee (EC)… […]
…given to applicants who are already engaged in clinical practice or research in HD and have a realistic prospect of remaining active in the HD field following completion of the… […]
…Manifest Huntington’s Disease. No. of study participants and sites: This open-label study aims to recruit participants from 2 sites in France. For further information see the clinical trial registration…. […]
no event… […]
…Supporting young people, all over the world, impacted by Huntington’s disease. This event is open to all HD community members: family and professional…. […]
…disease, and their treatments on quality of life? An opportunity is currently open through an EU call to apply for a collaborative project to strengthen the evidence base for available… […]